AR015412A1 - Derivados de hidantoina que muestran una actividad inhibidora contra la farnesil transferasa, procedimiento para su preparacion y composicion anti-cancerque comprende a dichos derivados - Google Patents

Derivados de hidantoina que muestran una actividad inhibidora contra la farnesil transferasa, procedimiento para su preparacion y composicion anti-cancerque comprende a dichos derivados

Info

Publication number
AR015412A1
AR015412A1 ARP980103683A ARP980103683A AR015412A1 AR 015412 A1 AR015412 A1 AR 015412A1 AR P980103683 A ARP980103683 A AR P980103683A AR P980103683 A ARP980103683 A AR P980103683A AR 015412 A1 AR015412 A1 AR 015412A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
substituted
halogen
represents hydrogen
unsubstituted
Prior art date
Application number
ARP980103683A
Other languages
English (en)
Spanish (es)
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of AR015412A1 publication Critical patent/AR015412A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP980103683A 1997-07-26 1998-07-27 Derivados de hidantoina que muestran una actividad inhibidora contra la farnesil transferasa, procedimiento para su preparacion y composicion anti-cancerque comprende a dichos derivados AR015412A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019970035333A KR19990012061A (ko) 1997-07-26 1997-07-26 파네실 전이효소 저해제로 유용한 하이덴토인 유도체

Publications (1)

Publication Number Publication Date
AR015412A1 true AR015412A1 (es) 2001-05-02

Family

ID=19515820

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980103683A AR015412A1 (es) 1997-07-26 1998-07-27 Derivados de hidantoina que muestran una actividad inhibidora contra la farnesil transferasa, procedimiento para su preparacion y composicion anti-cancerque comprende a dichos derivados

Country Status (7)

Country Link
EP (1) EP1000036A1 (ko)
JP (1) JP2001510829A (ko)
KR (2) KR19990012061A (ko)
AR (1) AR015412A1 (ko)
AU (1) AU729341B2 (ko)
WO (1) WO1999005117A1 (ko)
ZA (1) ZA986623B (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1255737A4 (en) * 1999-09-06 2003-04-16 Lg Chem Investment Ltd PROCESS FOR THE PREPARATION OF 5-HYDROXYMETHYLIMIDAZOLE SUBSTITUTED IN 1
WO2003018135A1 (en) 2001-08-24 2003-03-06 Wyeth Holdings Corporation Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase
WO2003018554A1 (en) 2001-08-24 2003-03-06 Wyeth Holdings Corporation 3-substituted-3-(substitutedsulfonyl or sulfanyl)pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase
WO2003018011A1 (en) 2001-08-24 2003-03-06 Wyeth Holdings Corporation 5-(substituted)-5-(substitutedsulfonyl or sulfanyl)thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase
CN1671387A (zh) * 2002-07-31 2005-09-21 欧洲凯尔特股份有限公司 芳基取代的乙内酰脲化合物及其作为钠通道阻滞剂的应用
US20060116366A1 (en) * 2002-12-04 2006-06-01 Parmee Emma R Spirocyclic ureas, compositions containing such compounds and methods of use
TW200621766A (en) * 2004-09-17 2006-07-01 Hoffmann La Roche Substituted hydantoins
US7612212B2 (en) * 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
KR101147583B1 (ko) 2007-08-16 2012-05-21 에프. 호프만-라 로슈 아게 치환 히단토인
US20110038924A1 (en) * 2007-10-29 2011-02-17 Goomer Randal S Osteoarthritis gene therapy
KR20100086503A (ko) * 2007-12-20 2010-07-30 에프. 호프만-라 로슈 아게 Ｍｅｋ 키나아제 저해제로서의 치환된 히단토인
WO2014019092A1 (en) * 2012-08-01 2014-02-06 The Hospital For Sick Children Inhibitors of peptidyl arginine deiminase (pad) enzymes and uses thereof
ES2686353T3 (es) * 2013-12-31 2018-10-17 Ipsen Pharma S.A.S. Nuevos derivados de imidazolidino-2,4-diona
KR101593205B1 (ko) 2015-06-12 2016-02-11 김윤태 유리창 청소장치

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0219363A (ja) * 1988-07-06 1990-01-23 Fujisawa Pharmaceut Co Ltd イミダゾリジン誘導体
DE4009506A1 (de) * 1990-03-24 1991-09-26 Hoechst Ag Hydantoinderivate
DE4126277A1 (de) * 1991-08-08 1993-02-11 Cassella Ag Hydantoinderivate
JPH0931060A (ja) * 1995-07-25 1997-02-04 Nissan Chem Ind Ltd 環状ウレア化合物の製造法
JP3449084B2 (ja) * 1995-12-25 2003-09-22 富士レビオ株式会社 ヒダントイン誘導体

Also Published As

Publication number Publication date
AU8464798A (en) 1999-02-16
ZA986623B (en) 1999-01-26
AU729341B2 (en) 2001-02-01
WO1999005117A1 (en) 1999-02-04
KR19990014070A (ko) 1999-02-25
KR19990012061A (ko) 1999-02-25
JP2001510829A (ja) 2001-08-07
EP1000036A1 (en) 2000-05-17
KR100384116B1 (ko) 2003-08-30

Similar Documents

Publication Publication Date Title
AR015412A1 (es) Derivados de hidantoina que muestran una actividad inhibidora contra la farnesil transferasa, procedimiento para su preparacion y composicion anti-cancerque comprende a dichos derivados
HUP0000591A2 (hu) Fémproteáz inhibitor hatású piperazin-, morfolin- és tiomorfolin-származékok és alkalmazásuk gyógyszerkészítmények előállítására
ATE390404T1 (de) Aminderivate, ihre herstellung und verwendung als inhibitoren der produktion von amyloid-beta
AR034253A1 (es) Compuestos activadores de glucoquinasa que contienen hidantoina sustituida, un procedimiento para su preparacion, composiciones farmaceuticas, procedimientos para su preparacion, empleo de los mismos para la preparacion de medicamentos
AR017236A1 (es) Compuestos biciclo [2.2.1] heptanos, composiciones farmaceuticas, procedimientos para tratar
NO991957D0 (no) Nye benzotiofen, benzofuran og indolforbindelser, en fremgangsmÕte ved deres fremstilling og farmas°ytiske sammensetninger inneholdende dem
BRPI0509364B8 (pt) derivados de tetraidroquinolina, composição farmacêutica que os compreende e um processo por preparar os referidos derivados
RS50339B (sr) Jedinjenja indazola i farmaceutske kompozicije za inhibiranje protein kinaza i postupci za njihovu upotrebu
MX9202142A (es) Nuevos derivados de urea, proceso para su preparacion, y composicion farmaceutica que los comprende.
AR002955A1 (es) Un compuesto heterocíclico substituido, procedimiento y compuestos intermediarios para su preparación y composición farmacéutica que contiene a dicho compuesto.
AR019427A1 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa, procedimiento para su preparacion, su uso para la preparacion de medicamentos, composiciones farmaceuticas y compuestos intermediarios utiles para su preparacion
YU21597A (en) Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation
AR005419A1 (es) Un compuesto derivado de piridinona, sus usos, un proceso para prepararlo, y una composicion farmaceutica que lo comprende
AR012181A1 (es) Un derivado de pirimidina, procedimientos para prepararlo, una composicion farmaceutica que lo comprende, y un compuesto util como intermediario parapreparar dicho derivado de pirimidina.
AR053109A1 (es) DERIVADOS DE PIPERIDINA Y PIPERAZINA, UN METODO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU USO EN LA ELABORACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR EL RECEPTOR DE QUIMIOQUINA CCR2.
AR016644A1 (es) Compuestos de 2-aminopiridinas con sustituyentes alcoxi ramificados, composicion farmaceutica y uso para la manufactura de medicamentos
AR008621A1 (es) Un compuesto derivado de amina succinica, un procedimiento para llevar a cabo su preparacion y una composicion farmaceutica que comprende dichocompuesto
DK72686D0 (da) Aminosyrederivat og antikonvulsant praeparat som indeholder derivatet
ES8201167A1 (es) Procedimiento para la obtencion de derivados de cefalospori-nas
ATE127117T1 (de) 1-aryl-1-hydroxy-1-substituierte-3-(4- substituierte-1-piperazinyl)-2-propanone und ihre verwendung bei der behandlung von blasenstörungen neurologischen ursprungs.
PE20040750A1 (es) Derivados de n-(1-acetilpiperidin-4-il)-4-benzidril-2-isopropilpiperazin-1-carboxamida como inhibidores de 17beta-hidroxiesteroide deshidrogenasa de tipo 3
MX9603998A (es) Agonista receptor de 5-ht3, derivado de tiazol novedoso e intermediario del mismo.
AR018632A1 (es) Compuestos derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico, su uso en la fabricacion de medicamentos, composicion farmaceutica que los contiene, proceso para su preparacion.
DK266686A (da) 1-aryl-5-alkoximinoalkylaminopyrazoler, fremgangsmaader til fremstilling deraf og deres anvendelse som herbicider og vaekstregulatorer
AR026222A1 (es) Compuestos derivados de acido antranilico

Legal Events

Date Code Title Description
FB Suspension of granting procedure